Troy A. Ignelzi - 21 Feb 2023 Form 4 Insider Report for Karuna Therapeutics, Inc.

Role: Chief Financial Officer
Signature: /s/ Troy Ignelzi
Issuer symbol: N/A
Transactions as of: 21 Feb 2023
Net transactions value: -$1,084,860
Form type: 4
Filing time: 23 Feb 2023, 15:37:23 UTC
Previous filing: 13 Feb 2023
Next filing: 24 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KRTX	Common Stock	Options Exercise	$55,200	+6,000	+20%	$9.20^*	36,487	21 Feb 2023	Direct
transaction	KRTX	Common Stock	Sale	$1,140,060	-6,000	-16%	$190.01	30,487	21 Feb 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KRTX	Option (right to buy)	Options Exercise	$0	-6,000	-5.5%	$0.000000	103,726	21 Feb 2023	Common Stock	6,000	$9.20	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2022.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $189.96 to $190.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3	This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter.